Here are four takeaways:
1. Nuvectra is a medical device company developing a neurostimulation technology platform for chronic pain treatment.
2. The company’s main product, Algovita, is a spinal cord stimulation system.
3. The funds will help Nuvectra introduce Algovita to the U.S. market.
4. The credit facility includes a $40 million senior secured term loan and a $5 million line of credit.
More articles on devices:
Amedica, SI-BONE, Stryker & more: 14 key notes
Stryker completes CareFusion’s VCF acquisition: 5 takeaways
FDA panel finds Cartiva SCI safe, effective: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
